Long-term air pollution, cardiometabolic multimorbidity, and genetic

1

22

susceptibility: a multi-state modeling study of 415,855 participants 2 3 Xu Gao<sup>1#</sup>, Meijie Jiang<sup>1 #</sup>, Ninghao Huang<sup>2</sup>, Xinbiao Guo<sup>1</sup>, Andrea A. Baccarelli<sup>3</sup>, Tao Huang<sup>2</sup> 4 5 6 <sup>1</sup>Department of Occupational and Environmental Health Sciences, School of Public Health, Peking 7 University. <sup>2</sup>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 8 9 China 10 <sup>3</sup>Laboratory of Environmental Precision Health, Mailman School of Public Health, Columbia 11 University, New York, NY, USA 12 #Contributed to the study equally 13 14 **Corresponding author:** Xu Gao, Ph.D. 15 Department of Occupational and Environmental Health Sciences 16 School of Public Health, Peking University 17 18 No.38 Xueyuan Road, Haidian District Beijing, China 100191 19 Phone: +86-136-2190-8907 20 Email: xu.gao@pku.edu.cn 21

ORCID: https://orcid.org/0000-0001-6506-6084

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

**Abstract Background:** Cardiometabolic multimorbidity (CMM) with at least two cardiometabolic diseases (CMDs) including type II diabetes (T2D), ischemic heart disease (IHD), and stroke, is a global health problem with multiplicative mortality risk and deserves to be investigated as a top priority. Although air pollution is a leading modifiable environmental risk for individual CMD, its impacts on CMM progression were poorly understood. **Objective:** To elucidate the impact of air pollution on CMM progression, individually and in the context of genetic preposition. **Design:** Multi-state modeling cohort study. **Setting:** Data were extracted from the UK Biobank. Participants: 415,855 eligible UK Biobank adults that were free of CMDs at baseline. Measurements: Annual concentrations of particulate matter (PM) with a diameter of ≤2.5 µm  $(PM_{2.5}), 2.5-10 \mu m (PM_{2.5-10}), and \le 10 \mu m (PM_{10}), and nitrogen oxides (NO<sub>x</sub> and NO<sub>2</sub>) were$ estimated using Land Use Regression model. **Results:** During a median follow-up of 8.93 years, 33,375 participants had a first CMD (FCMD), and 3,257 subsequently developed CMM. PM<sub>2.5</sub>, PM<sub>10</sub>, NO<sub>2</sub>, and NO<sub>x</sub> levels, as well as their combined exposure were associated with increased FCMD risks and even higher risks of CMM. Particularly, per a 5-µg/m<sup>3</sup> increase in PM<sub>2.5</sub>, risks for FCMD and CMM increased by 27% (95% confidence interval: 20%-34%) and 41% (18%-68%), respectively. By FCMD types, participants with IHD had a higher risk of CMM than those with T2D or stroke. Eighty-five CMD-related genetic variants were associated with CMM trajectories in our study and associations of air pollution with FCMD and CMM risks could be aggravated progressively with increasing genetic risks.

- Limitations: Other major air pollutants including ozone and SO<sub>2</sub> were not considered due to the data 45
- 46 availability.
- **Conclusions:** Air pollution has profound adverse health impacts on the progression of CMM through 47
- multi-stage dynamics, especially for individuals with IHD and high genetic risk. 48

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Introduction Multimorbidity is defined as the simultaneous presence of two or more chronic diseases and is an increasing global health problem with impaired quality of life, reduced life expectancy, and elevated cost of health care resources by a larger scale than any chronic conditions individually (1). Cardiometabolic multimorbidity (CMM), as one of the most common multimorbidity patterns (2), refers to the coexistence of two or three most prevalent cardiometabolic diseases (CMDs), including type II diabetes (T2D), ischemic heart disease (IHD), and stroke (2, 3). A study based on 91 cohorts identified that any combination of these CMDs was associated with multiplicative mortality risk, and life expectancy was substantially lower in people with CMM with a reduction of life expectancy up to 15 years (3). CMM, therefore, is not simply an accumulation of the three healthy conditions but rather a collision of risk factors promoting death. Up to date, there is a dearth of studies on the determinants of CMM, which is urgently needed to seek appropriate management approaches to early prevent and control CMM development (4). Ambient air pollution, especially fine particulate matter (PM<sub>2.5</sub>, aerodynamic diameter  $<2.5 \mu m$ ), has been recognized as a modifiable risk factor for CMDs (5, 6). For instance, a meta-analysis identified a robust positive association between PM exposure and the incidence of T2D (7). Petal et al. also reported that a 10  $\mu$ g/m<sup>3</sup> increase in PM<sub>2.5</sub> and particulate matter (PM) of sizes 10  $\mu$ m (PM<sub>10</sub>) was associated with 0.25% higher IHD mortality and 0.27% higher IHD morbidity (8). Short-term air pollution exposure could also increase the daily hospital admissions for ischemic stroke (9). Understanding the impact of air pollution on the dynamics of CMM thereby could hint targeted population of CMM prevention. Nevertheless, this is not sufficient to depict the risks of CMM

coming from air pollution exposure without accounting for the temporal development of CMM using traditional time-to-event analyses. Additionally, CMDs have been suggested to be affected mutually by environmental exposures and genetic profiles (10), but knowledge on whether the genetic predisposition of CMM and air pollution could jointly promote the CMM development remains unknown.

Therefore, we aimed to investigate the associations of five pollutants (PM2.5, PM2.5-10, PM10, NO2, and NOx) with the CMM trajectories using the scheme of multi-state modeling in the UK Biobank. The multi-state model could evaluate the risk of five transient states (baseline CMD-free to first CMD [FCMD], baseline to death, FCMD to CMM, FCMD to death, and CMM to death) on occupying another state (11). Leveraging in-depth genetic information, this study additionally allowed us to explore the potential synergetic effect of genetic profile and air pollution on CMM.

83 Methods Study design and participants 84 85 UK Biobank is a large population-based prospective cohort study (12). As previously described, about 0.5 million UK residents aged 37-73 years were enrolled from 2006-2010, and the end date of 86 87 follow-up was 31 December 2018. Their information collected includes lifestyle and health data, physical measurements, and biological samples. After excluding participants without information on 88 air pollution, CMDs, and selected covariates, and those with T2D, IHD, and stroke at baseline, a total 89 90 of 415,855 participants without diagnosis of the three CMDs were included in our study for further 91 analyses to exclude the impact of baseline CMD on the association between air pollution and CMM trajectories (Figure S1). The UK Biobank was approved by the North West Multicenter Research 92 93 Ethical Committee. All participants provided informed written consent. This research has been 94 conducted using the UK Biobank Resource under Application Number 44430. 95 Cardiometabolic diseases and mortality 96 97 Incident IHD, stroke, and T2D cases, as well as relevant mortality, were retrieved from primary care and hospital admission data using the UK National Health Services register. We used the 98 International Classification of Diseases 10th revision (ICD-10) and primary care health records to 99 identify relevant diagnoses. IHD was defined by codes I20 to I25. Stroke was defined by codes I60 100 to I69. T2D was diagnosed based on the following criteria: having fasting glucose ≥7.0 mmol/L or 2-101 hour plasma glucose ≥11.1 mmol/L, having physician-diagnosed diabetes, using diabetes medication, 102 103 or with ICD-10 code E11.

104

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

Genetic information and genetic risk scores

Exposure assessments Annual 1-year moving average ambient concentrations of PM<sub>2.5</sub>, PM<sub>2.5-10</sub>, PM<sub>10</sub>, NO<sub>2</sub>, and NO<sub>x</sub> were calculated with a Land Use Regression (LUR) model. Details about the LUR model are in the supplement methods. Previous reports using leave-one-out cross-validation demonstrated good model performance for PM<sub>2.5</sub>, PM<sub>10</sub>, NO<sub>2</sub> and NO<sub>x</sub> (R<sup>2</sup> of cross-validation =77%, 88%, 87% and 88%, respectively) and a moderate performance for  $PM_{coarse}$  (cross-validation  $R^2=57\%$ ). Concentrations of PM<sub>2.5</sub>, PM<sub>2.5-10</sub>, and NO<sub>x</sub> were available in 2010 only, while concentrations of PM<sub>10</sub> (2007 and 2010) and NO<sub>2</sub> (2005, 2006, 2007, and 2010) were collected for multiple years. Since the baseline enrollment was conducted from 2006 to 2010, to better fit the time frame of baseline survey, we used averaged levels of PM<sub>10</sub> and NO<sub>2</sub> in this study. To explore the combined impact of air pollutants, we weighted the levels of PM<sub>2.5</sub>, PM<sub>10</sub>, NO<sub>x</sub>, and NO<sub>2</sub> using the  $\beta$  coefficients retrieved from the transition process from baseline to FCMD based on Cox regression models adjusting for all covariates described below. PM<sub>2.5-10</sub> was removed due to its null associations with CMDs (see the Result section for details). This approach was validated in a 10-fold cross-validation analysis in a previous air pollution-related study based on UK Biobank (13, 14). Weighted indicator (termed as "co-exposure score") was estimated as: co-exposure score =  $(\beta_{\text{[PM2.5]}} \times \text{PM}_{2.5} + \beta_{\text{[PM10]}} \times \text{PM}_{10} + \beta_{\text{[NO2]}} \times \text{NO}_2 + \beta_{\text{[NOx]}} \times \text{NO}_x) \times (4/\text{sum of the } \beta \text{ coefficients}).$ The co-exposure score ranged from 36.50 to 141.78. Participants were divided into five groups based on the quintiles.

Detailed information about genotyping, imputation, and quality control in UK Biobank has been described previously (15) and provide in supplement methods. Based on previous genome-wide association studies (GWASs) (16-18), we retrieved 74 single-nucleotide polymorphisms (SNPs) for T2D, 55 for IHD, and 32 for stroke (Table S1). We first coded each SNP as 0 and 1 according to the existence of risk alleles to test their independent associations with CMM using MSM and then selected 85 SNPs that were nominal significantly related to any processes of CMM development (see the Result section for details) to create a weighted genetic risk score (GRS). Each selected SNP was then recoded as 0, 1, or 2 according to the number of risk alleles, and multiplied by the logarithmic odds ratios (ORs) obtained from the previous GWAS to calculate the GRS as previously described (19). The GRS ranged from 57.4 to 117.9, with a higher score indicating a higher genetic risk of CMM.

## Covariates

As previously reported (20), the following potential covariates were retrieved from the baseline questionnaires and physical examinations, including age, sex (male/female), body mass index (BMI), years of education (<10 years/≥10 years), race (based on UK Biobank question "self-reported ethnic group", categorized into White, Black, Asian, and other; other included those reported "white and black mixed" and "other ethnic group" to the question), smoking status (never, former, current), employment status (employed/unemployed), total household income (≥£31000/ <£31000), moderate alcohol intake status (yes/no), and high-level physical activity status (yes/no). Detailed measures of the covariates were described in supplement methods.

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

Statistical analysis Survival time for each participant was calculated as the duration from the response date of baseline to the date of incident, death, or date of censoring, whichever came first. We first used Cox regression to examine the associations of five pollutants with FCMD, CMM, and death, separately. Proportional hazard assumptions were not violated based on the Schoenfeld residuals test. Previously described covariates were adjusted in the models. We then used the unidirectional multi-state model (MSM) to assess five pollutants in the temporal disease development from free of CMDs to FCMD, CMM, and death. The MSM was carried out with Markov proportional hazards (21, 22), which is an extension of competing risks survival analysis allowing estimation of the role of a certain factor in different phases of a process. If a participant was recorded with at least two events (CMDs and/or death) at the same time point simultaneously, we theoretically assumed that the order of disease occurrence was T2D, IHD, and stroke according to previous evidence (3, 23, 24), and died eventually. Times for the previous disease were accordingly minus 0.5 days. First, five transition processes were constructed according to the natural history of CMM and previous studies (24, 25) (transition pattern A, Figure 1): (I) from baseline to FCMD; (II) from baseline to death from a disease other than T2D, IHD, and stroke; (III) from FCMD to CMM; (IV) from FCMD to death from any causes; and (V) from CMM to death from any causes. Processes I, III, and V were the primary ones with the most interest of study in our analysis. Then, to explore which CMD was associated with higher risks of CMM, we further used the MSMs to analyze the effects of air pollutants on different pathways from baseline to CMM by dividing the FCMDs into T2D, IHD, and stroke separately. Thus, along with processes II and V of pattern A, the processes I,

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

III, and IV of pattern A were further divided into nine sub-transitions (Ia-Ic; IIIa-IIIc, IVa-IVc) in pattern B (transition pattern B, Figure 1). Restricted cubic spline regression models were then used to evaluate the dose–response relationship between air pollutants and each CMM processes with 3 knots (10<sup>th</sup>, 50<sup>th</sup>, and 90<sup>th</sup> percentiles of exposures). To clarify the effects of genetic susceptibility and air pollution on CMM, we tested the gene-air pollution interaction first using the MSM with an interaction term of the continuous co-exposure score and CMM-related SNPs and continuous GRS to examine the potential modifying effect of genetic background. In the case that interaction effect did not meet criteria for statistical significance (p-values<0.05), we generated a series of categorical variable based on the quintiles of co-exposure score and binary GRS (by median) to assess their joint effects on CMM development. Six sensitivity analyses were conducted to validate the robustness of our findings. First, we constructed another weighted co-exposure score based on PM<sub>2.5</sub>, NO<sub>2</sub>, and NO<sub>x</sub> to understand whether the marginal association of  $PM_{10}$  with CMM may distort the findings towards null. Then we conducted the MSM of pattern A by adjusting for baseline diet behavior, and levels of low-density lipoprotein, high-density lipoprotein, triglycerides, total cholesterol, systolic blood pressure, and diastolic blood pressure, all of which were established to be related to CMD and their subsequent outcomes (26). Furthermore, we conducted the MSM of pattern A by adjusting for ten genetic principal components of UK Biobank and also in the white participants only to ensure the reliability of our findings across different ethnicities. To understand the impact of mobilization on our findings, we additionally conducted the MSM of pattern A in participants who self-reported that he/she had

been living at the same baseline address for more than five years. Last, we evaluated whether the age at FCMD onset (<65 years or ≥65 years) could modify the association between air pollution and subsequent CMM. All analyses were conducted using R (version 4.0.1). MSM was performed using "mstate" package of R. A two-tailed *p*-value <0.05 indicated statistical significance.

193

194

195

196

197

198

**Results** 199 Descriptive analysis 200 201 Detailed characteristics of the eligible 415,855 participants are shown in Table S2. The mean  $\pm$ standard deviation (SD) age at baseline was 56.23±8.09 years. Most participants (94.83%) were 202 203 white. Nearly half of the participants were former or never smokers with moderate alcohol intake, 204 and had a total household income ≥£31,000. During a median follow-up of 8.93 years, a total of 33,375 participants (8.03%) experienced FCMD. Among them, about half experienced IHD 205 (N=16,385), 13,533 experienced T2D, and 3,007 experienced strokes (Figure 1). The mean (SD) 206 207 ambient levels of PM<sub>2.5</sub>, PM<sub>2.5-10</sub>, PM<sub>10</sub>, NO<sub>2</sub>, and NO<sub>x</sub> were 9.97 (1.05), 6.42 (0.90), 19.28 (1.95), 29.08 (9.21), and 43.74 (15.56) µg/m<sup>3</sup>, respectively. The pollutants were mutually correlated with 208 each other (Figure S2, p-values <0.001). 209 210 Associations between air pollution and cardiometabolic multimorbidity 211 Patten A was our primary model of CMM development (Figure 1). Fully-adjusted Cox models 212 213 showed that PM<sub>2.5</sub>, PM<sub>10</sub>, NO<sub>2</sub>, and NO<sub>x</sub> were associated with the risks of FCMD, CMM, and death, respectively (Table S3). The MSM was therefore useful to uncover the underlying risks of CMM 214 215 development. Figure 2 depicted that PM<sub>2.5</sub>, NO<sub>2</sub>, and NO<sub>x</sub> were significantly associated with all 216 CMM processes except for CMM-death. PM<sub>10</sub> was marginally related to baseline-FCMD and subsequently to CMM. The risk estimates of the four air pollutants were much higher for FCMD-217 CMM or FCMD-death than for baseline-FCMD. For instance, per 5-µg/m<sup>3</sup> increment, PM<sub>2.5</sub> was 218 219 associated with 27% higher risk of the whole population to develop FCMD from baseline (95% 220 confidence intervals [CIs]: 20%-34%), 41% higher risk of individuals with FCMD to progress from

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

FCMD to CMM (95% CI: 18%-68%), and 35% higher risk of individuals with FCMD to progress from FCMD to death (95% CI: 11%-63%). Same increases in NO<sub>x</sub> and NO<sub>2</sub> demonstrated similar significant magnitudes but with reduced estimates. PM<sub>2.5-10</sub> had null associations with all CMM processes. Monotonic increasing dose-response relationships were observed for the associations of PM<sub>2.5</sub>, NO<sub>x</sub>, and NO<sub>2</sub> with the processes of baseline-FCMD, FCMD-CMM, and FCMD-death (Figures 3 & S3). Strong associations between the co-exposure score based on PM<sub>2.5</sub>, PM<sub>10</sub>, NO<sub>x</sub>, and NO<sub>2</sub> and the CMM processes were also observed, except for CMM-death (Figures 2 & S3-S4). Compared to the 1<sup>st</sup> quintile of the co-exposure score, the 5<sup>th</sup> quintile was associated with 14% (95% CI: 10%-18%), 22% (95% CI: 7%-38%), and 22% (95% CI: 7%-40%) higher risks for processes of baseline-FCMD, FCMD-CMM, and FCMD-death, respectively. A sensitivity analysis using the modified co-exposure score based on PM<sub>2.5</sub>, NO<sub>2</sub>, and NO<sub>x</sub> also yielded similar estimates (Table S4). In transition pattern B which classified FCMDs into three CMDs (Figure 1), we found baseline participants were more likely to initially develop T2D than IHD or stroke (Tables S5 & S6). However, FCMD participants with IHD were more likely to develop CMM than those with T2D or stroke in response to PM<sub>2.5</sub>, NO<sub>2</sub>, NO<sub>3</sub>, and the co-exposure score (Table 1). For instance, per a 5µg/m<sup>3</sup> increase in PM<sub>2.5</sub>, the corresponding hazard ratios (HRs) of CMM were 1.51 (95% CI: 1.08-2.10), 1.05 (95% CI: 1.01-1.10), and 1.01 (95% CI: 0.88-1.15) for FCMD participants with IHD, T2D, and stroke, respectively.

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

Genetic susceptibility of cardiometabolic multimorbidity and joint effects with air pollution For the retrieved CMD-related SNPs, 38 T2D-related, 32 IHD-related, and 15 stroke-related loci were nominally associated with any CMM trajectories of pattern A (Tables S1 & S7 a-c, nominal pvalues <0.05). Genes ABO, EDNRA, FURIN, MIA3, and CDKN2B-AS1 had >2 unique SNPs, and CDKN2B-AS1 had the most including rs3217992, rs4977574, and rs7859727. The weighted GRS based on these CMM-related loci was robustly associated with CMM transitions (Table S7). However, none of the SNPs or the continuous GRS could interact with the co-exposure score in relation to CMM trajectories (Table S6 d-f, interaction FDR-corrected p>0.05; Table S9, interaction p-values >0.1). And in the mutual adjustment model, the coefficients of GRS and the co-exposure score remained essentially unchanged compared to models with either factor (Table S9). We suggested that the environmental and genetic factors were independently associated with CMM development. Given no interaction was observed, we generated a series of categorical variable based on the quintiles of co-exposure score and dichotomized GRS (by median) to test the joint effects of both factors. We observed gradients in associations of higher GRS and co-exposure score for the processes of baseline-FCMD and FCMD-CMM (Figure 4). For instance, FCMD participants with the 5<sup>th</sup> quintile co-exposure score and a high GRS had a higher risk of CMM compared to those with the 1<sup>st</sup> quintile of co-exposure score and a low GRS with a HR of 1.40 (95% CI: 1.16-1.70) (Table S19). But no significant joint effects on baseline-death, FCMD-death, or CMM-death was found. Sensitivity analyses

In the model which further adjusted for baseline diet behavior, lipoprotein levels, and blood pressure, (Table S11), the estimates of  $PM_{2.5}$ ,  $NO_2$ ,  $NO_3$ , and the co-exposure score remained essentially unchanged in relation to the risks of CMM development. Results from models with additional adjustment with genetic principal components (Table S12) and from models conducted in white participants only (Table S13) also showed similar risks, both of which suggested the robustness of our findings across the ethnicities. Similar estimates were also yielded in participants living in the address for more than five years (Tables S14), suggesting that out primary results were fairly robust regardless of the mobilization. Moreover, although the interactions between the age of FCMD onset (<65 years or  $\geq$ 65 years) and air pollution on the CMM risks were not significant (Table S15, interaction p-values >0.2), air pollution—CMM associations were stronger among the elderly aged <65 years than those aged  $\geq$ 65 years.

276 Discussion

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

Utilizing the prospective data of ~0.42 million participants of the UK Biobank, we uniquely found that PM<sub>2.5</sub>, NO<sub>2</sub>, and NO<sub>x</sub> levels were associated with the CMM individually and jointly as a weighted co-exposure score in a multi-state nature. For participants with any FCMD, those with IHD had higher risks of incident CMM and death than those who had T2D or stroke as FCMD. Risks for developing FCMD and CMM under long-term air pollution could be enhanced by the CMM genetic susceptibility. Our findings will help broaden the scope of public health recommendations encompassing patients with CMDs and to better characterize and distinguish individuals with a high risk of developing CMM under environmental insults. To date, there is an evident lack of studies that have specifically investigated the temporal association between air pollution and CMM through methods that involve a stochastic process covering the possible stages of multimorbidity rather than simply counting the numbers of non-communicable diseases without considering disease-disease interactions (27). This study is the first investigation showing the critical role of air pollution on the dynamics of CMM, which indicates that historical air pollution exposure, especially to PM<sub>2.5</sub> may have profound and lasting impacts on cardiovascular and metabolic systems. In consistent with previous studies of individual CMDs (6, 7, 28), our study yielded robust associations of air pollution, especially PM<sub>2.5</sub>, NO<sub>2</sub>, and NO<sub>x</sub>, with FCMD. Moreover, we identified a stepwise increasing magnitude of the associations of each air pollutant with the risks of CMM and death after the occurrence of FCMD. This pattern highlights the value of the secondary prevention of individuals with FCMD to mitigate the additive risks of subsequent CMDs or death. Additionally, although not statistically significant, individuals with a younger age at FCMD

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

diagnosis (<65 years) had higher CMM risk than those older. Future studies are warranted to elucidate whether the age at FCMD onset could be recognized as a potential risk indicator of subsequent CMM risk for the precision prevention of CMM along with environmental risk factors. More intriguingly, we found that participants were more likely to develop T2D first from baseline under air pollution. This may be plausible that increased blood glucose level has been recognized as a critical pathophysiology mechanism for the risks of IHD and stroke (23). We thus believed that T2D could occur ahead of the onset of IHD or stroke and could be easily diagnosed in routine health examinations. Furthermore, previous evidence implied that those with IHD or stroke could have relatively higher glucose levels or were pre-diabetic because cardiovascular events may impair fasting glucose (29). Even not yet reached the diagnosis criteria of T2D, we anticipated those with IHD or stroke to be more likely to develop T2D and CMM. However, in our study, participants with IHD as FCMD showed higher risks of developing CMM or death than others who first had T2D and stroke. The attenuated risks related to stroke could be explained by better medical care of stroke patients than those with IHD because of the sudden onset of stroke and higher mortality than IHD. Additionally, stroke patients usually receive better and systematic blood pressure and glucose management over rehabilitation period which may considerably lower their risks of IHD, T2D, and/or death (30, 31). Therefore, for areas with relatively higher stroke incidence and heavier burden of air pollution, for instance, in developing countries, CMM prevention for stroke patients may be more than valuable (32). Additionally, except for the limited death numbers, null associations between air pollution and the CMM-death process may be explained by better medical care for CMM patients. A recent study of CMM and mortality in UK general practices have demonstrated

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

that compared with people with individual CMDs, those with multimorbidity could have a higher likelihood of receiving evidence-based treatment to lower the exceeded risk of coexisting cardiovascular and metabolic diseases (33). Accumulating evidence has suggested the biological pathway of CMD resulting from air pollution (34), including pro-hypertension, insulin resistance, and endothelial damage resulting from oxidative stress and/or inflammation, which could further promote CMM (28, 34). Beyond these common etiological pathways, a recent study showed that the comorbidity of cardiovascular and metabolic diseases could be explained by overlapping genetic profiles along with protein-protein interactions (PPIs) as a complex network (35). In line with this, our study found that four out of the five CMMrelated genes (i.e., ABO, EDNRA, FURIN, and MIA3) that had  $\geq 2$  unique SNPs were related to protein-coding and could additionally participate in PPIs of the cardiovascular network. Gene CDKN2B-AS1 with the most CMM-related SNPs is not a protein-coding gene, but it produces a long non-coding RNA that interacts with nearby genes and impairs the interferon-y signaling response to elevate the susceptibility of CMDs (36). Since this gene has also been related to multiple agingrelated diseases including cancer and glaucoma, as well as abnormalities in blood cell counts (37), more work is required to uncover its role in the development of multimorbidity. Moreover, insignificant interaction between air pollution and GRS was observed, but moderate additive effect of genetic background on the associations of air pollution with the baseline-FCMD and FCMD-CMM processes were shown. Therefore, we believe that genetic susceptibility could be considered in

CMM prevention in response to air pollution. Such mild clues based on SNPs reported by previous

GWAS of CMDs further suggest the identification of novel CMM-related variants is highly recommended to empower the risk prediction of CMM.

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

This study has several strengths including the large sample size and detailed records of CMD with information on lifestyle and covariates that allowed us to conduct the state-of-art multi-state analysis. Several limitations should also be noted in the result interpretation. First, we only focused on the CMM defined with the co-occurrence of three diseases including IHD, stoke, and T2D only because this multimorbidity pattern is the most observed and studied in previous literature (2, 3). Other important CMDs such as hyperlipidemia, and nonalcoholic fatty liver disease could be investigated in future studies. Second, UK Biobank is a volunteer cohort with participants who were likely healthier than the general population, and we excluded those with pre-existing CMDs. Both may cause selection bias influencing the effect of air pollution on CMM development towards null as relatively healthier people usually have lower risks of CMDs. Furthermore, the air pollution data was mostly a single measurement of the annual average level without any further measures within a shorter time interval. This prohibited further explorations on the lag or short-term (<1 month) influences of air pollution. Meanwhile, we did not have the data on other major air pollutants, such as ozone and sulfur dioxide, which have been associated with CVD and T2D (38, 39) and could be studied in future multi-state investigations. Additionally, in processing the data to match the multistate algorithm, we theoretically ascertained the occurrence orders of events if subjects have two or more events reported on the same day. This may reduce the power of MSM but very slightly because the number of cases with such conditions was comparatively tiny (N=1192, ~3.6% of FCMD participants). Moreover, despite that we created the GRS using a GWAS of CMM based on well-

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

established SNPs that were highly related to any CMD in previous GWASs, its generalizability in predicting CMM may be required to be further validated. Last, we did not have the drug use information of the participants during follow-up, which may considerably mitigate the risks of subsequent adverse cardiometabolic health outcomes. Given the CMD information was mostly retrieved from linkage to electronic health records, we believe that most CMD participants received appropriate treatment. Such well-received CMD management may have underestimated the substantial relevant detrimental impacts of air pollution on CMM development we observed. Notwithstanding the improved awareness of the public on the harms of air pollution, knowledge is quite limited about whether the impact of environmental exposure on cardiovascular or metabolic systems may further lead to relevant comorbidities. In this study, we suggest air pollution could increase the risk of CMM in almost a decade through multi-stage dynamics, especially for FCMD participants with IHD and participants with high genetic risk. Our results further elucidate the importance of CMM prevention after long-term air pollution exposure regardless of the genetic risk, especially for locations where air quality is poorer than in the UK and the burden of CMDs resulting from air pollution is thus expected to be heavier. For health professionals, general practitioners, and stakeholders, more efforts may be warranted to better protect the vulnerable population from environmental risks of CMM.

382

383

384

385

386

387

388

389

390

**Acknowledgments:** We thank Dr. Chen Chen for the language assistance. Funding: Dr. Xu Gao was supported by grants from the Peking University (BMU2021YJ044) and China CDC Key Laboratory of Environment and Population Health (2022-CKL-03). **Competing financial interests:** The authors have no conflict of interest to disclose. Data availability statement: Data are available in a public, open access repository. This research has been conducted using the UK Biobank Resource under Application Number 44430. The UK Biobank data are available on application to the UK Biobank (www.ukbiobank.ac.uk/).

391 References 392 1. Glynn LG. Multimorbidity: another key issue for cardiovascular medicine. Lancet. 393 2009;374(9699):1421-2. 394 2. Prados-Torres A, Calderon-Larranaga A, Hancco-Saavedra J, Poblador-Plou B, van den Akker M. 395 Multimorbidity patterns: a systematic review. J Clin Epidemiol. 2014;67(3):254-66. Emerging Risk Factors C, Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, et al. 396 3. 397 Association of Cardiometabolic Multimorbidity With Mortality. JAMA. 2015;314(1):52-60. 398 Atun R. Transitioning health systems for multimorbidity. Lancet. 2015;386(9995):721-2. 4. 399 5. Hamanaka RB, Mutlu GM. Particulate Matter Air Pollution: Effects on the Cardiovascular System. 400 Front Endocrinol (Lausanne). 2018;9:680. 401 6. Brook RD, Rajagopalan S, Pope CA, 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, et al. Particulate 402 matter air pollution and cardiovascular disease: An update to the scientific statement from the 403 American Heart Association. Circulation. 2010;121(21):2331-78. 7. Yang BY, Fan S, Thiering E, Seissler J, Nowak D, Dong GH, et al. Ambient air pollution and diabetes: 404 405 A systematic review and meta-analysis. Environ Res. 2020;180:108817. 406 8. Patel V, Kantipudi N, Jones G, Upton A, Kamath MV. Air Pollution and Cardiovascular Disease: A 407 Review. Crit Rev Biomed Eng. 2016;44(5):327-46. 408 9. Tian YH, Liu H, Zhao ZL, Xiang X, Li M, Juan J, et al. Association between ambient air pollution and 409 daily hospital admissions for ischemic stroke: A nationwide time-series analysis. Plos Medicine. 410 2018;15(10). 411 Ward-Caviness CK. A review of gene-by-air pollution interactions for cardiovascular disease, risk 10. 412 factors, and biomarkers. Hum Genet. 2019;138(6):547-61.

- 413 11. Amorim LD, Cai J. Modelling recurrent events: a tutorial for analysis in epidemiology. Int J Epidemiol.
- 414 2015;44(1):324-33.
- 415 12. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access
- 416 Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age.
- 417 Plos Medicine. 2015;12(3).
- Simon RM, Subramanian J, Li MC, Menezes S. Using cross-validation to evaluate predictive accuracy 418 13.
- 419 of survival risk classifiers based on high-dimensional data. Brief Bioinform. 2011;12(3):203-14.
- 420 Fan M, Sun D, Zhou T, Heianza Y, Lv J, Li L, et al. Sleep patterns, genetic susceptibility, and incident 14.
- 421 cardiovascular disease: a prospective study of 385 292 UK biobank participants. Eur Heart J.
- 422 2020;41(11):1182-9.
- 423 15. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide genetic data on
- 424 ~500,000 UK Biobank participants. bioRxiv. 2017:166298.
- 425 Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 16.
- 426 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet.
- 427 2015;47(10):1121-30.
- 428 Kwak SH, Park KS. Recent progress in genetic and epigenetic research on type 2 diabetes. Exp Mol 17.
- 429 Med. 2016;48:e220.
- 430 18. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry genome-
- 431 wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke
- 432 subtypes. Nat Genet. 2018;50(4):524-37.
- 433 19. Wang M, Zhou T, Song Y, Li X, Ma H, Hu Y, et al. Joint exposure to various ambient air pollutants
- 434 and incident heart failure: a prospective analysis in UK Biobank. Eur Heart J. 2021.

435 20. Gao X, Huang N, Guo X, Huang T. Role of sleep quality in the acceleration of biological aging and its 436 potential for preventive interaction on air pollution insults: Findings from the UK Biobank cohort. Aging 437 Cell. 2022:e13610. 438 Putter H. Tutorial in biostatistics: competing risks and multi-state models. Statistics in medicine. 21. 439 2007;26(11):2389-430. 440 22. de Wreede LC. The mstate package for estimation and prediction in non- and semi-parametric multi-441 state and competing risks models. Computer methods and programs in biomedicine. 2010;99(3):261-442 74. 443 23. Benn M, Tybjaerg-Hansen A, McCarthy MI, Jensen GB, Grande P, Nordestgaard BG. Nonfasting 444 glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study. J Am 445 Coll Cardiol. 2012;59(25):2356-65. 446 24. Han Y, Hu Y, Yu C, Guo Y, Pei P, Yang L, et al. Lifestyle, cardiometabolic disease, and multimorbidity 447 in a prospective Chinese study. Eur Heart J. 2021;42(34):3374-84. 448 25. Singh-Manoux A, Fayosse A, Sabia S, Tabak A, Shipley M, Dugravot A, et al. Clinical, 449 socioeconomic, and behavioural factors at age 50 years and risk of cardiometabolic multimorbidity 450 and mortality: A cohort study. PLoS Med. 2018;15(5):e1002571. 451 Kelsey MD, Nelson AJ, Green JB, Granger CB, Peterson ED, McGuire DK, et al. Guidelines for 26. 452 Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison. J Am 453 Coll Cardiol. 2022;79(18):1849-57. 454 27. Forman DE, Maurer MS, Boyd C, Brindis R, Salive ME, Horne FM, et al. Multimorbidity in Older Adults 455 With Cardiovascular Disease. J Am Coll Cardiol. 2018;71(19):2149-61.

Rajagopalan S, Al-Kindi SG, Brook RD. Air Pollution and Cardiovascular Disease: JACC State-of-the-

456

28.

- Art Review. J Am Coll Cardiol. 2018;72(17):2054-70. 457 458 29. Mozaffarian D, Marfisi R, Levantesi G, Silletta MG, Tavazzi L, Tognoni G, et al. Incidence of new-459 onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the 460 effect of clinical and lifestyle risk factors. Lancet. 2007;370(9588):667-75. 461 30. Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet. 2011;377(9778):1693-702. Saxena A, Anderson CS, Wang X, Sato S, Arima H, Chan E, et al. Prognostic Significance of 462 31. 463 Hyperglycemia in Acute Intracerebral Hemorrhage: The INTERACT2 Study. Stroke. 2016;47(3):682-464 8. 465 32. Dugravot A, Fayosse A, Dumurgier J, Bouillon K, Rayana TB, Schnitzler A, et al. Social inequalities in 466 multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II 467 cohort study. Lancet Public Health. 2020;5(1):e42-e50. 468 33. Canoy D, Tran J, Zottoli M, Ramakrishnan R, Hassaine A, Rao S, et al. Association between 469 cardiometabolic disease multimorbidity and all-cause mortality in 2 million women and men registered in UK general practices. BMC Med. 2021;19(1):258. 470 471 34. Al-Kindi SG, Brook RD, Biswal S, Rajagopalan S. Environmental determinants of cardiovascular 472 disease: lessons learned from air pollution. Nat Rev Cardiol. 2020;17(10):656-72. 473 35. Dong G, Feng J, Sun F, Chen J, Zhao XM. A global overview of genetically interpretable 474 multimorbidities among common diseases in the UK Biobank. Genome Med. 2021;13(1):110. 475 36. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, et al. 9p21 DNA variants 476 associated with coronary artery disease impair interferon-gamma signalling response. Nature. 477 2011;470(7333):264-8.
  - Melzer D, Pilling LC, Ferrucci L. The genetics of human ageing. Nat Rev Genet. 2020;21(2):88-101. 37.

479 38. Chen R, Jiang Y, Hu J, Chen H, Li H, Meng X, et al. Hourly Air Pollutants and Acute Coronary 480 Syndrome Onset In 1.29 Million Patients. Circulation. 2022;0(0). 481 39. Zhang S, Mwiberi S, Pickford R, Breitner S, Huth C, Koenig W, et al. Longitudinal associations 482 between ambient air pollution and insulin sensitivity: results from the KORA cohort study. Lancet 483 Planet Health. 2021;5(1):e39-e49. 484

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

exposure score;

**Figure Legends** Figure 1 Numbers (percentages) of participants in transition pattern A (solid line) and B (dashed line) from baseline to first cardiometabolic disease (FCMD), cardiometabolic multimorbidity (CMM), and death. Figure 2 Associations of five air pollutants and co-exposure score with the risks of first cardiometabolic disease and cardiometabolic multimorbidity of pattern A using multi-state model Models adjusted for age, sex, ethnicity, BMI, years of education, smoking status, moderate alcohol intake, high-level physical activity, total household income, and employment status. Estimates of air pollutants were demonstrated per 5-ug/m3 increase and estimates of co-exposure score were demonstrated per one SD increase. Dots: Point estimate; Error bar: 95% confidence limits; Figure 3 Graphs of the dose-response relationships of five air pollutants and co-exposure score with the processes from baseline to FCMD and from FCMD to CMM of pattern A Solid lines: point estimates; Shadows: 95% confidence limits; Figure 4 Joint associations of weighted genetic risk and air pollution levels of five transition processes on pattern A using multi-state model 0: low GRS & 1st quintile of co-exposure score (reference); 1: low GRS & 2nd quintile of coexposure score; 2: low GRS & 3<sup>rd</sup> quintile of co-exposure score; 3: low GRS & 4<sup>th</sup> quintile of coexposure score; 4: low GRS & 5<sup>th</sup> quintile of co-exposure score; 5: high GRS & 1<sup>st</sup> quintile of coexposure score; 6: high GRS & 2<sup>nd</sup> quintile of co-exposure score; 7: high GRS & 3<sup>rd</sup> quintile of coexposure score; 8: high GRS & 4th quintile of co-exposure score; 9: high GRS & 5th quintile of co-

**Supplementary Materials** 509 Figure S1 Flowchart of participant selection 510 511 Figure S2 Correlation matrix of the ambient levels of five air pollutants 512 Figure S3 Graphs of the dose-response relationships of five air pollutants and co-exposure score with the trajectories of cardiometabolic multimorbidity of pattern A (a: PM<sub>2.5</sub>; b: PM<sub>2.5-10</sub>; c: PM<sub>10</sub>; d: 513 514  $NO_2$ , e:  $NO_x$ , f: co-exposure score) Figure S4 Associations of categorical co-exposure score (quintiles) with the trajectories of 515 516 cardiometabolic multimorbidity of pattern A using multi-state model Models adjusted for age, sex, ethnicity, BMI, years of education, smoking status, moderate alcohol 517 518 intake, high-level physical activity, total household income, and employment status. 519 520 **Table S1** Characteristics of genetic variants associated with type II diabetes, ischemic heart disease, 521 and stroke 522 523 Table S2 Baseline characteristics of 415,855 participants by incident disease status during follow-up 524 **Table S3** Associations of five air pollutants with the risks of first cardiometabolic disease, cardiometabolic multimorbidity, and mortality using Cox model 525 Table S4 Associations of the co-exposure score based on PM<sub>2.5</sub>, NO<sub>2</sub>, and NO<sub>x</sub> with the trajectories 526 527 of cardiometabolic multimorbidity of pattern A using multi-state model 528 **Table S5** Associations of air pollution with the trajectories of cardiometabolic multimorbidity of pattern B using multi-state model 529 530 **Table S6** Associations of categorical co-exposure score (quintiles) with the trajectories of cardiometabolic multimorbidity of pattern B using multi-state model 531

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549


550


551


552


553

**Table S7** Associations of CMD-related genetic variants with the trajectories of cardiometabolic multimorbidity of pattern A using multi-state model (a-c) and their interactions with co-exposure score (d-f) **Table S8** Associations of weighted genetic risk score with the trajectories of cardiometabolic multimorbidity of pattern A using multi-state model **Table S9** Mutual associations of co-exposure score and genetic risk score with the trajectories of cardiometabolic multimorbidity of pattern A using multi-state model in model with and without interaction terms **Table S10** Joint associations of weighted genetic risk score and co-exposure score of five transition states on pattern A using multi-state model **Table S11** Associations of air pollution with the trajectories of cardiometabolic multimorbidity of pattern A using multi-state model additionally adjusted for baseline diet behaviors, cholesterol levels, and blood pressure **Table S12** Associations of air pollution with the trajectories of cardiometabolic multimorbidity of pattern A using multi-state model additionally adjusted for genetic principal components **Table S13** Associations of air pollution with the trajectories of cardiometabolic multimorbidity of pattern A using multi-state model in white participants **Table S14** Associations of air pollution with the trajectories of cardiometabolic multimorbidity of pattern A using multi-state model in participants living in the baseline address for more than five years **Table S15** Associations of air pollution with the trajectories of cardiometabolic multimorbidity of pattern A using multi-state model by the age of having the first cardiometabolic disease









**Table 2** Associations of five air pollutants and co-exposure score with the risks of first cardiometabolic disease, cardiometabolic multimorbidity, and death after the first cardiometabolic disease of pattern B using multi-state model <sup>a</sup>

Air pollutants	PM <sub>2.5</sub>	PM2.5-10	PM <sub>10</sub>	NO <sub>2</sub>	NOx	Co-exposure score <sup>a</sup>
Trajectories	HR (95% CI)					
Baseline→T2D	1.47 (1.34, 1.60)	1.86 (1.12, 3.08)	1.79 (1.40, 2.30)	1.21 (1.15, 1.28)	1.12 (1.09, 1.15)	1.08 (1.06, 1.10)
<b>Baseline→IHD</b>	1.13 (1.04, 1.22)	0.76 (0.48, 1.21)	0.76 (0.61, 0.95)	0.98 (0.93, 1.02)	1.03 (1.00, 1.05)	1.01 (1.00, 1.03)
<b>Baseline</b> → <b>Stroke</b>	1.23 (1.02, 1.48)	1.89 (0.65, 5.51)	1.26 (0.75, 2.11)	1.04 (0.93, 1.16)	1.05 (0.98, 1.11)	1.03 (0.99, 1.08)
T2D→CMM	1.05 (1.01, 1.10)	1.01 (0.96, 1.06)	1.01 (0.99, 1.04)	1.00 (1.00, 1.01)	1.00 (1.00, 1.01)	1.05 (1.00, 1.10)
IHD→CMM	1.51 (1.08, 2.10)	0.90 (0.12, 6.56)	1.24 (0.46, 3.35)	1.28 (1.04, 1.58)	1.15 (1.04, 1.27)	1.10 (1.02, 1.18)
Stroke→CMM	1.01 (0.88, 1.15)	0.92 (0.78, 1.09)	0.98 (0.91, 1.06)	1.01 (1.00, 1.02)	1.00 (0.98, 1.01)	0.99 (0.85, 1.14)
T2D→Death	1.03 (0.97, 1.10)	0.99 (0.92, 1.07)	1.01 (0.98, 1.05)	1.00 (1.00, 1.01)	1.00 (1.00, 1.01)	1.04 (0.97, 1.11)
IHD→Death	1.10 (1.04, 1.17)	0.95 (0.88, 1.02)	1.03 (1.00, 1.07)	1.01 (1.01, 1.02)	1.01 (1.00, 1.01)	1.13 (1.06, 1.20)
Stroke→Death	1.01 (0.92, 1.10)	0.94 (0.84, 1.04)	1.01 (0.96, 1.07)	1.01 (1.00, 1.02)	1.00 (0.99, 1.01)	1.02 (0.93, 1.12)

a: Models adjusted for age, sex, ethnicity, BMI, years of education, smoking status, moderate alcohol intake, high-level physical activity, total household income, and employment status. Estimates of air pollutants were demonstrated per 5-µg/m³ increase and estimates of co-exposure score were demonstrated per one SD increase. Bolded-values were statistically significant (*p*-values <0.05).